As a matter of fact, two recent studies in mouse models of breast and lung cancer demonstrated that blockade of efferocytosis with an anti-MerTK antibody promotes tumor antigen presentation by infiltrating myeloid cells and triggers Type I IFN immune response as well as CD8+ T cells and NK mediated tumor immunity, resulting in tumor rejection and abscopal effect (36, 37). Here, MERTK is linked to lung carcinoma.